Secukinumab attenuates reactive astrogliosis via IL-17RA/(C/EBP β)/SIRT1 pathway in a rat model of germinal matrix hemorrhage.

CONCLUSION: Secukinumab attenuated reactive astrogliosis and reduced neurological deficits after GMH, partly by regulating IL-17RA/(C/EBPβ)/SIRT1 pathways. Secukinumab may provide a promising therapeutic strategy for GMH patients. PMID: 31020769 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31020769?dopt=Abstract

Source: CNS Neuroscience and Therapeutics - April 23, 2019 Category: Neuroscience Authors: Liu SP, Huang L, Flores J, Ding Y, Li P, Peng J, Zuo G, Zhang JH, Lu J, Tang JP Tags: CNS Neurosci Ther Source Type: research

More News: Brain | Hemorrhagic Stroke | Neurology | Neuroscience